Navigation Links
Detection of Mutant K-ras in a Kindred With Hereditary Pancreatic Cancer by DGGE

David A. Crispin,* Ru Chen,* Michael B. Kimmey,** Teresa A. Brentnall**
* Departments of Pathology and
**Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington.


Introduction

Pancreatic cancer is the fourth leading cause of cancer death in the U.S. and its frequency is rising. At the time of diagnosis, 9699% of patients are incurable and will shortly die. Current methods to evaluate patients for pancreatic adenocarcinoma include Endoscopic Retrograde Cholangiopancreatography (ERCP), abdominal CT, ultrasound, and serum markers. These methods of diagnosis are often insensitive or equivocal in early disease. Tumorigenesis is believed to involve the K-ras oncogene, DCC, p16, APC, bcl-2 and p53 tumor suppressor genes; screening for mutations or loss of heterozygosity in these genes may provide better diagnostic tests that are more sensitive and specific.1 The study of families in which cancer is inherited in an autosomal dominant fashion has provided considerable insight into understanding the molecular basis for pancreatic cancer. We have previously reported an extensive kindred in which pancreatic cancer is inherited in an autosomal dominant fashion and is associated with development of pancreatic insufficiency prior to the diagnosis of cancer.2 We have utilized the DCode system for denaturing gradient gel electrophoresis (DGGE) to identify patient samples with K-ras mutations.


Materials and Methods

Genomic DNA was isolated from tissue or from fluid obtained from patients at ERCP. K-ras exon 1 was amplified from genomic DNA using a thermal cycler and primers as described by Imai et al.3 Amplifications were carried out using 300 ng of DNA template in a buffer containing 10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, pH 8.3, with 2 units of Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN), 200 M dNTPs, and 15 pmol of each primer in a total volume of 50 liters. Reactions were denatured for 3 minutes at 95 C, which was followed by thirty seven cycles with the following profile: 95 C (20s), 55 C (60s), 72 C (40s). The 110 bp product was run on a 3% agarose gel and visualized using ethidium bromide staining.

Successful samples were run on a 10% acrylamide 080% perpendicular DGGE gel at 150 V for 2 hours at 56 C, then stained with ethidium bromide to find the optimal conditions for parallel DGGE (Figure 1). This was determined to be 30%60%. Samples were then run on a parallel DGGE gel at 56 C for 4 to 5 hours at 150 V, and stained with ethidium bromide. Positive samples were sequenced using dye terminator chemistry and run on an ABI Prism (Perkin Elmer).


Results

Exon 1, containing codons 12 and 13, of the K-ras gene was examined for the presence of k-ras mutations by DGGE. Constitutional and pancreatic tissues or pancreatic juice in eight of the family members were evaluated. All samples that were positive by DGGE (Figure 2) were confirmed by DNA sequencing. Three of these individuals had K-ras mutations in codon 13 present in pancreatic cancer or precancerous tissue and three had mutations in codon 12. There was no evidence of K-ras mutation in the metastatic pancreatic cancer tissue from individual III.19, even when DNA was subcloned, or from the ERCP fluid or dysplastic tis sue from III.15 (Table 1).


Discussion

K-ras mutations are a common event in pancreatic adenocarcinoma. Screening for K-ras mutations along with a panel of other markers may prove useful in early diagnosis of this disease. DGGE is a practical tool in screening samples for the presence of such mutations.


References

1. Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., Goodman, S. N., Sohn, T. A., Hruban, R. H., Yeo, C .J. and Kern, S. E., Cancer Res., 57(9), 17311734 (1997).

2. Evans, J. P., Burke, W., Chen, R., Bennett, R. L., Schmidt, R. A., Dellinger, E. P., Kimmey, M., Crispin, D., Brentnall, T. A. and Byrd, D. R., J. Med. Genet., 32(5), 330335 (1995).

3. Imai, M., Tomokazu, H. and Ogawa, K., Cancer, 73(11), 27272733 (1991).


back to top
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Simple, Sensitive, and Rapid Detection of FLAG -Tagged Fusion Proteins
2. A New PCR-based Mycoplasma Detection Method
3. HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex Virus DNA
4. Detection and Identification of Phosphorylation Sites in Proteins Using LC/MS/MS with Neutral Fragment Loss Mapping
5. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
6. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
7. The DIG System Nonradioactive and Highly Sensitive Detection of Nucleic Acids
8. Quantitative Measurement of Cell Proliferation Using the BrdU ELISA: A Comparison Between Colorimetric and Chemiluminescent Detection
9. Quantification of Nucleosomes in Serum by the Cell Death Detection ELISAplus
10. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
11. In Situ Cell Death Detection Kit
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):